MXPA05013460A - Compuestos de n-{piperazina '4-sustituida-1-sulfonilmetil-alquil}-n-hidroxiformamida como inhibidores de metaloproteinasas. - Google Patents

Compuestos de n-{piperazina '4-sustituida-1-sulfonilmetil-alquil}-n-hidroxiformamida como inhibidores de metaloproteinasas.

Info

Publication number
MXPA05013460A
MXPA05013460A MXPA05013460A MXPA05013460A MXPA05013460A MX PA05013460 A MXPA05013460 A MX PA05013460A MX PA05013460 A MXPA05013460 A MX PA05013460A MX PA05013460 A MXPA05013460 A MX PA05013460A MX PA05013460 A MXPA05013460 A MX PA05013460A
Authority
MX
Mexico
Prior art keywords
alkyl
ring
aryl
hydroxyfomamide
aco4
Prior art date
Application number
MXPA05013460A
Other languages
English (en)
Inventor
Maurice Raymond Verscho Finlay
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27656653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05013460(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA05013460A publication Critical patent/MXPA05013460A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invencion proporciona compuestos de la formula (I) (ver formula (I)): o una sal, profarmaco o solvato farmaceuticamente aceptable de los mismos, en donde el anillo B representa un anillo arilo monociclico que tiene seis atomos de anillo o un anillo heteroarilo monociclico que tiene hasta seis atomos de anillo y que contiene uno o mas heteroatomos de anillo, en donde cada uno de estos heteroatomos es nitrogeno; R2 representa un grupo seleccionado de alquilo o arilo de C1-6, este grupo siendo sustituido por uno o mas grupos fluor; n es 1, 2 o 3 y R1 representa un grupo sustituido opcionalmente seleccionado de alquilo de C1-6, cicloalquilo de C5-7, heterocicloalquilo, arilo, heteroarilo, alquilo de C1-6-arilo, alquilo de C1-6-heteroarilo, alquilo de C1-6cilcoalquilo o alquilo de C1-6-heterocicloalquilo. Se proporcionan procedimientos para su preparacion; composiciones farmaceuticas que los contienen y su uso en el tratamiento de una condicion de enfermedad mediada por una o mas enzimas metaloproteinasa.
MXPA05013460A 2003-06-27 2004-06-23 Compuestos de n-{piperazina '4-sustituida-1-sulfonilmetil-alquil}-n-hidroxiformamida como inhibidores de metaloproteinasas. MXPA05013460A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301922A SE0301922D0 (sv) 2003-06-27 2003-06-27 Novel compounds
PCT/GB2004/002702 WO2005000822A1 (en) 2003-06-27 2004-06-23 N-{‘4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
MXPA05013460A true MXPA05013460A (es) 2006-03-09

Family

ID=27656653

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013460A MXPA05013460A (es) 2003-06-27 2004-06-23 Compuestos de n-{piperazina '4-sustituida-1-sulfonilmetil-alquil}-n-hidroxiformamida como inhibidores de metaloproteinasas.

Country Status (34)

Country Link
US (1) US7485644B2 (es)
EP (1) EP1644340B1 (es)
JP (1) JP4701167B2 (es)
KR (1) KR20060026440A (es)
CN (2) CN102229589A (es)
AR (1) AR044931A1 (es)
AT (1) ATE414063T1 (es)
AU (1) AU2004251104B2 (es)
BR (1) BRPI0411929A (es)
CA (1) CA2529468A1 (es)
CO (1) CO5650254A2 (es)
CY (1) CY1108757T1 (es)
DE (1) DE602004017733D1 (es)
DK (1) DK1644340T3 (es)
ES (1) ES2315675T3 (es)
HK (1) HK1086835A1 (es)
HR (1) HRP20090009T3 (es)
IL (1) IL172615A0 (es)
IS (1) IS8257A (es)
MX (1) MXPA05013460A (es)
MY (1) MY138680A (es)
NO (1) NO20060444L (es)
NZ (1) NZ544208A (es)
PL (1) PL1644340T3 (es)
PT (1) PT1644340E (es)
RU (1) RU2351595C2 (es)
SA (1) SA04250224B1 (es)
SE (1) SE0301922D0 (es)
SI (1) SI1644340T1 (es)
TW (1) TW200524898A (es)
UA (1) UA81491C2 (es)
UY (1) UY28387A1 (es)
WO (1) WO2005000822A1 (es)
ZA (1) ZA200510458B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427403D0 (en) 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
DK1951674T3 (da) * 2005-10-26 2012-01-02 Merck Serono Sa Sulfonamidderivater og anvendelse deraf til modulation af metalloproteinaser
CN101007794B (zh) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
ES2592154T3 (es) * 2010-07-08 2016-11-28 Kaken Pharmaceutical Co., Ltd. Derivado de N-hidroxiformamida y medicamento que contiene el mismo

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2317455C (en) 1998-01-30 2011-01-25 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
JP2003501414A (ja) * 1999-06-04 2003-01-14 アストラゼネカ・アクチエボラーグ メタロプロテイナーゼの阻害剤
UA73155C2 (en) * 2000-02-21 2005-06-15 Astrazeneca Ab Substituted by piperidine and piperazine n-hydroxyformamides as metalloproteinase inhibitors
GB0119472D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
AU2003221786A1 (en) * 2002-04-25 2003-11-10 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
WO2004113312A1 (en) * 2003-06-19 2004-12-29 Celltech R & D Limited Hydroxamate sulfonamides as cd23 shedding inhibitors

Also Published As

Publication number Publication date
NZ544208A (en) 2009-02-28
SA04250224B1 (ar) 2009-05-31
AU2004251104A1 (en) 2005-01-06
ATE414063T1 (de) 2008-11-15
HRP20090009T3 (en) 2009-02-28
JP2007516164A (ja) 2007-06-21
JP4701167B2 (ja) 2011-06-15
NO20060444L (no) 2006-03-22
ZA200510458B (en) 2007-03-28
PL1644340T3 (pl) 2009-04-30
PT1644340E (pt) 2009-01-02
RU2005141058A (ru) 2006-07-27
US7485644B2 (en) 2009-02-03
CO5650254A2 (es) 2006-06-30
KR20060026440A (ko) 2006-03-23
MY138680A (en) 2009-07-31
US20070197542A1 (en) 2007-08-23
DK1644340T3 (da) 2009-02-02
UA81491C2 (en) 2008-01-10
WO2005000822A1 (en) 2005-01-06
SE0301922D0 (sv) 2003-06-27
EP1644340B1 (en) 2008-11-12
CA2529468A1 (en) 2005-01-06
CY1108757T1 (el) 2014-04-09
RU2351595C2 (ru) 2009-04-10
AR044931A1 (es) 2005-10-12
CN1812974B (zh) 2011-06-29
AU2004251104B2 (en) 2008-05-08
TW200524898A (en) 2005-08-01
HK1086835A1 (en) 2006-09-29
BRPI0411929A (pt) 2006-08-15
CN102229589A (zh) 2011-11-02
ES2315675T3 (es) 2009-04-01
SI1644340T1 (sl) 2009-02-28
DE602004017733D1 (de) 2008-12-24
UY28387A1 (es) 2005-01-31
CN1812974A (zh) 2006-08-02
IL172615A0 (en) 2006-04-10
EP1644340A1 (en) 2006-04-12
IS8257A (is) 2006-01-23

Similar Documents

Publication Publication Date Title
EP0393457B1 (en) Proteinase inhibitor
NO20055568L (no) Substituerte 1,4-diazepiner og anvendelser derav
MXPA05007496A (es) Tienopirimidindionas y su uso en la modulacion de enfermedades autoinmunes.
MXPA04001016A (es) Derivados de sulfonamida como inhibidores de la gamma secretasa.
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
SE0400284D0 (sv) Novel compounds
NO20050741L (no) Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
NO20054095L (no) Pyridyloksymetyl og benzioksazolazabicyklisk derivater
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
NO20060383L (no) Substituerte diketopiperaziner og deres anvendelse som oksytocinantagonister
SE9703377D0 (sv) New compounds
EA200500717A1 (ru) Новые соединения имидазопиридина, способ их получения и фармацевтические композиции, которые их содержат
TNSN07395A1 (en) Novel phenyl-pyridinyl-piperazine derivatives, a method for the production thereof and pharmaceutical compositions containing said derivatives
HUP0201722A2 (hu) Gyógyászati készítmények alkoholizmus és alkoholfüggőség kezelésére
HUP0303737A2 (hu) 6-helyzetben szubsztituált indolinonok és alkalmazásuk kináz inhibitorokként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
NO20060444L (no) N-{4'-substituerte piperazin-1-sulfonylmetylalkyl}-N-hydroksyformamid forbindelser som metallproteinaseinhibitorer
MXPA05007563A (es) Inhibidores de la integrasa del vih, composiciones farmaceuticas y metodos para su uso.
IL148875A0 (en) Sulfonyl hydrazide derivatives, their preparation and pharmaceutical compositions containing them
HUP0204501A2 (hu) Gyűrűs vegyületek, ezeket tartalmazó gyógyászati készítmények, valamint eljárás a vegyületek előállítására és alkalmazásuk
AR021968A1 (es) Oximas e hidrazonas sustituidas como antagonistas de neuroquinina
EA200600551A1 (ru) Соединения пиперазина, способ их получения и фармацевтические композиции, которые их содержат
EA200101204A1 (ru) Новые бициклические соединения аминопиразинона, способ их получения и содержащие их фармацевтические композиции
ES2169716T3 (es) Nuevos derivados de 2,3-metano-aminoacidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ATE449760T1 (de) Nichtpeptidinhibitoren von matrixmetalloproteinasen

Legal Events

Date Code Title Description
FG Grant or registration